Fox Run Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$717K Buy
+37,136
New +$836K 0.13% 285
2025
Q4
Sell
-23,759
Closed -$715K 1194
2025
Q3
$715K Buy
23,759
+7,070
+42% +$212K 0.11% 346
2025
Q2
$607K Buy
+16,689
New +$602K 0.1% 387
2023
Q3
Sell
-4,887
Closed -$225K 941
2023
Q2
$225K Buy
+4,887
New +$227K 0.06% 543
2022
Q4
Sell
-13,355
Closed -$553K 840
2022
Q3
$553K Buy
+13,355
New +$686K 0.22% 139
2022
Q2
Sell
-5,392
Closed -$392K 711
2022
Q1
$392K Buy
+5,392
New +$375K 0.22% 166
2021
Q3
Sell
-5,364
Closed -$511K 591
2021
Q2
$511K Buy
+5,364
New +$559K 0.46% 40
2019
Q3
Sell
-3,214
Closed -$204K 524
2019
Q2
$204K Buy
+3,214
New +$205K 0.14% 368
2018
Q1
Sell
-11,453
Closed -$531K 885
2017
Q4
$531K Buy
11,453
+7,453
+186% +$365K 0.16% 266
2017
Q3
$213K Buy
+4,000
New +$237K 0.06% 589
2016
Q1
Sell
-2,600
Closed -$292K 528
2015
Q4
$292K Buy
+2,600
New +$260K 0.23% 170

Other funds holding RARE